Quarterly ResultAug 5, 2026, 04:14 PM
Paysign Q2 2026 Revenue $28.25M, Up 48.1%; Raises Full-Year Outlook
AI Summary
Paysign, Inc. reported record financial results for the second quarter of 2026, with revenue increasing 48.1% to $28.25 million. This growth was driven by strong performance in both its patient affordability and plasma businesses, leading to a significant rise in GAAP net income to $6.76 million and Adjusted EBITDA to $9.61 million. The company also raised its full-year 2026 outlook for both revenue and Adjusted EBITDA, reflecting continued momentum and a robust pipeline of opportunities.
Key Highlights
- Q2 2026 revenue was $28.25 million, a 48.1% increase from Q2 2025.
- Pharma revenue grew 88.9% to $14.65 million, adding 51 net patient affordability programs.
- Plasma revenue increased 21.4% to $13.04 million, despite a decrease of 46 net plasma centers.
- GAAP net income reached $6.76 million, or $0.11 per diluted share, up 386.9% YoY.
- Adjusted EBITDA increased 113.0% to $9.61 million, or $0.16 per diluted share.
- Exited the quarter with $27.37 million in unrestricted cash and zero bank debt.
- Raised full-year 2026 revenue outlook to $114.0 million - $117.0 million.
- Raised full-year 2026 Adjusted EBITDA outlook to $35.0 million - $38.0 million.
Price Impact
More from PAYS